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Bacterial artiﬁcial chromosome (BAC) clones have proven invaluable for genetic manipulation of herpesvirus genomes. BAC
cloning can also be useful for capturing representative genomes that comprise a viral stock or mixture. The Towne live attenuated
cytomegalovirus vaccine was developed in the 1970s by serial passage in cultured ﬁbroblasts. Although its safety, immunogenicity,
and eﬃcacy have been evaluated in nearly a thousand human subjects, the vaccine itself has been little studied. Instead, genetic
composition and in vitro growth properties have been inferred from studies of laboratory stocks that may not always accurately
represent the viruses that comprise the vaccine. Here we describe the use of BAC cloning to deﬁne the genotypic and phenotypic
properties of viruses from the Towne vaccine. Given the extensive safety history of the Towne vaccine, these BACs provide a logical
starting point for the development of next-generation rationally engineered cytomegalovirus vaccines.
1.Introduction
Cytomegalovirus (CMV) is a common cause of intrauterine
infection, aﬀecting 0.5–3% of all newborns worldwide. Each
year in the United States, an estimated 8,000 babies are
bornwithsymptomaticCMVinfectionsthatresultinserious
complications including hearing loss, vision impairment,
and varying degrees of mental retardation [1]. Another
6% to 23% of infants born infected but asymptomatic at
birth will develop sensorineural hearing loss [2]. Overall,
congenitalCMVinfectionsaccountforonefourthofallcases
of sensorineural hearing loss in the United States [3]. This
diseaseburdencouldbepreventedbyaneﬀectivevaccine[4].
The Towne vaccine is a live vaccine attenuated by ex-
tensive passage in human ﬁbroblasts [5]. It has been used
in nearly 1000 volunteers with no serious side eﬀects [6].
In renal transplant patients, Towne reduced CMV-associated
disease but did not prevent recipients from acquiring CMV
infections [7]. When used at a very low dose, it also failed
to protect immunocompetent mothers from acquiring CMV
infections from their children [8]. These results suggest
that Towne may be overattenuated and that by deﬁning,
characterizing, and selectively repairing attenuating muta-
tions, modiﬁed next-generation Towne-based vaccines with
enhanced eﬃcacy could be engineered.
However, current Towne strain molecular clones, se-
quences,andphenotypicdatadonotderivefromthevaccine,
but from laboratory stocks that, due to serial distribution
among research laboratories and attendant plaque puriﬁca-
tions, may have diverged from the viruses that comprise the
vaccine. The reference stock ATCC VR-977 is a laboratory
stockthatpredatestheC-107vaccinelot(S.Plotkin,personal
communication). VR-977 is comprised of a roughly 50/50
mixture of two genome variants: the Towne-varS (varS)
genome contains large b/b  sequence repeats and a 13kb
deletion from the UL/b  region that removes 15 genes,2 Journal of Biomedicine and Biotechnology
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Figure 1: Genome maps of Towne-varS, Towne-varL, and BAC-cloned viruses. Inverted repeats b/b  and c/c  (grey boxes) ﬂank unique long
(UL) and unique short (US) regions to delineate long and short genome segments. One or more copies of the a sequence (black bars) can
be found at long segment termini and inverted at the long and short segment junction (b a c ), while one or no copies are found at short
segment termini [9,10] (for simplicity singlecopies areshown). Dashed lines indicate UL sequences in varL that are missingfrom varS; black
boxes represent the BAC ori cassette (BAC). Nucleotide positions are indicated; genome features are approximately to scale.
whereas the Towne-varL (varL) genome retains the UL
sequences that are deleted from varS and has short (59-
bp) b/b  repeats (Figure 1)[ 9, 11–13]. Existing sequence
data and bacterial artiﬁcial chromosome (BAC) clones of
Towne genomes also derive either from laboratory stocks
of uncertain provenance or from VR-977. Moreover, viruses
with varL genomes are incompletely characterized [9].
Indeed,onlyrecently,bysequencingtheVR-977mixture,has
it been possible to reconstruct an approximation of the varL
genome; although within regions common to both genome
types, 18 polymorphisms were detected that could not be
assigned to particular variants [13].
To identify potential attenuating mutations in viruses
that comprise the vaccine and to establish deﬁned molecular
clones of known provenance for future development of
modiﬁed Towne-based vaccines, BAC clones were derived
from the vaccine with minimal passage in vitro. One BAC
clone representing varL was fully sequenced and compared
to the sequence obtained from VR-977, laboratory stocks of
varS, and wild-type clinical isolates in order to establish a
minimum set of attenuating mutations for the vaccine.
2.MaterialsandMethods
2.1. Cells and Virus. MRC-5 (ATCC CCL-171) and ARPE-
19 (ATCC CRL-2302) cells and CMV strain BADrUL131-
Y4 (a gift from Dai Wang and Thomas Shenk [14]) were
propagated as described [15]. Infected cells expressing green
ﬂuorescent protein (GFP) were visualized and photographed
using a Nikon Diaphot 300 inverted ﬂuorescence micro-
scope. Towne vaccine (lot C-107 [16]) was obtained from
the Wistar Institute, Philadelphia, Pa, USA. It was manu-
factured in 1989 by Program Resources, McLean, Va, USA
as lyophilized culture supernatant of MRC-5 cells infected
with passage 131 seed stock. One vial was reconstituted
with 1 ml sterile water and added to one 75cm2 ﬂask of
conﬂuent MRC-5 cells. After 1 week the culture medium was
collected as stock Towne P2. Representative Towne varS and
varL viruses were obtained from the vaccine by screening
viral clones isolated by limiting dilution with PCR reactions
speciﬁc for varS or varL genomes (not shown). Variant
designations were subsequently conﬁrmed by sequence and
restriction pattern analyses as described in Section 3.1.
2.2. BAC Cloning. Plasmid pYD-C29 was a gift from Dong
Y u .W h e nr e s t r i c t e dw i t hPmlI, it forms a linear fragment
containing LoxP-ﬂanked BAC origin (ori)s e q u e n c e sa n d
expression cassettes for GFP and puromycin N-acetyl trans-
ferase (puroR). This is ﬂanked by ∼1-kb recombination
sequencesfromtheUS28-US29 regionofCMVstrainAD169
[18] (see Figure 2(a)).
BAC clones TS15 and TL12 were obtained by transfec-
tion/infection in which 4µgPmeI-digested pYD-C29 DNA
was transfected into MRC-5 cells using jetPEI reagent
(Polyplus-transfection SA) followed two days later by infec-
tion (MOI = 1) with Towne P2. BAC clone TL17 was
obtained by cotransfection of MRC-5 cells using jetPEI with
10µgPmeI-digested pYD-C29 DNA and 17µg virion DNA
(puriﬁed, as previously described [19], from supernatants of
MRC-5 cells infected by Towne P2 stock). When extensive
CPE was reached, puromycin was added to a ﬁnal con-
centration of 1–3µg/mL. After 3-4 days, dead cells were
removed by washing, 105-106 fresh cells were added, and the
cultures were maintained without puromycin until extensive
CPE was reached. This process was repeated 2-3 times until
the majority of cells were GFP+. The supernatants were
transferredto50cm2 dishes,andDNAwasisolated24or72h
post infection (p.i.) and used to transform electrocompetent
E. coli as described previously [20].Journal of Biomedicine and Biotechnology 3
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Figure 2: Restriction analysis of BACs and BAC-derived viral genomes. (a) EcoRI and HindIII restriction maps illustrate restriction
fragments near the right end of BAC-cloned genomes that retain BAC ori. EcoRI T and HindIII V fragments (grey) are designated [17].
Genetic features of this region are illustrated, including the US28,B A Cori cassette, and US29 sequences in pYD-C29, CMV genes US29 to
TRS1,a n dc repeat with single terminal a sequence. (b–e) Restriction digests of virion DNAs made from the vaccine virus mixture (mix)
or varS and varL viruses isolated from the vaccine, virions from BAC-derived viruses (V), or circular BAC DNAs (B). Vb indicates TL17
virion DNA that retains the BAC ori; in all other BAC-derived viruses the BAC ori was excised. 4.2kb XbaI, 5.3kb EcoRI, and 3.0kb HindIII
fragments are unique to varS genomes, while 2.8 and 3.5kb BglII fragments are unique to varL genomes. BACs lack 4.5 and 3.5kb HindIII
and 4.4kb EcoRI fragments due to deletions and a 6.6kb EcoRI terminal fragment because they are circular. All BACs contain an unexpected
3.4kb BglII fragment due to a point mutation in the recombination vector. A 4.5kbBglII fragment that may arise from a single copy of the
a sequence is unique to TL17 virus with excised BAC ori.
2.3. Virus Reconstitution. Midiprep BAC DNA was prepared
asdescribedpreviously[20].GFP+virusesretainingtheBAC
ori were reconstituted by transfection of 10µg BAC DNA
into MRC-5 cells using jetPEI. BAC-ori-excised viruses were
obtained in the same way except that BAC DNA was co-
transfected with 1µg pCre DNA (a gift from Wolfram Brune
and Gabriele Hahn), and the resulting viruses were cloned
by limiting dilution in 96-well plates and screened to identify
wells containing GFP-negative viruses.
2.4. Viral Growth Curves. Conﬂuent MRC-5 cells in 75cm2
ﬂ a s k sw e r ei n f e c t e da tM O I so f0 . 1o r0 . 0 5 p f u / c e l l .T h e
cultures were washed 3h p.i. Culture supernatants were
titrated every 3 or 4 days for up to 14 days p.i. (d.p.i) using a
96-well method as described [20].
2.5. Sequencing. BAC TL12 was sequenced by the Genome
Center at Washington University. Sheared fragments of TL12
BAC DNA were separated electrophoretically using 0.8%
agarose. Fragments in the 4.0 to 6.5kb range were extracted
and subcloned into pSMART (Lucigen) and then sequenced
using a 3730 DNA analyzer (Applied Biosystems). The data
were assembled by Phrap (written by Phil Green). Coverage
was approximately 8X. The annotated sequence has been
deposited with GenBank (accession number GQ121041).
Targeted Sanger dideoxy sequencing was performed using
midiprep BAC or virion DNA templates. Sequencing primer
UL130-3(CAGACGCACCACAGAACGCAGAC)wasusedto
determine the presence or absence of the TT mutation in the
native UL130 locus.
3. Results
3.1. BAC Clones of VarS and VarL Derived from the Vaccine.
Infectious BAC clones were isolated with limited passage
of the vaccine in MRC-5 cells (see Section 2). As we4 Journal of Biomedicine and Biotechnology
did not plaque-purify recombinant viruses, BAC clones
were anticipated to reﬂect the mixture of varL and varS
genomes present in the vaccine. BAC clones were initially
screened by restriction analysis to identify clones with
apparently complete genomes and to diﬀerentiate varS and
varL clones. Based on available sequence from a VR-977-
derived varS genome (GenBank AY315197), a 4.2kb XbaI
fragment that spans the UL/b  region of varS was predicted
to be absent from varL genomes. Of 16 colonies resulting
from transfection/infection, XbaI restriction patterns were
identical, with the exception that 7 contained and 9 lacked
the 4.2kb XbaI fragment. Only 19 of 29 colonies resulting
from cotransfection appeared to contain complete genomes,
and of these, 3 contained and 16 lacked the 4.2kb XbaI
fragment (see data for representative clones, Figure 2(b)).
Selected BAC clones were tested for their ability to
reconstitute infectious viruses upon transfection into MRC-
5 cells. XbaI, HindIII, EcoRI, and BglII restriction patterns of
BACs and BAC-derived viral genomes were then compared
to patterns obtained from the vaccine-derived mixture and
from varS and varL viruses isolated from the vaccine by
limiting-dilutioncloning(seeSection 2).Figure 2showsdata
for one representative varS (TS15) and two representative
varL clones (TL12, TL17) that were selected based on ability
to reconstitute infectious virus and minimal restriction
pattern disparities with vaccine-derived viruses.
Restriction analyses revealed 5.3kb EcoRI and 3.0kb
HindIII fragments speciﬁc for varS genomes (Figures 2(c)
and 2(d)) and 2.8 and 3.5kbBglII fragments speciﬁcfor varL
genomes (Figure 2(e)) .A svi ra lg e n o m e sa r el i n e a r ,t h eyh a v e
terminal restriction fragments that are absent from circular
BACs. Consequently, all BAC DNAs lacked a 6.6kb terminal
EcoRI fragment from the left end of the genome, but this
fragment was restored in genomic DNA from BAC-derived
viruses (Figure 2(c)). BACs and BAC-derived viral genomes
alsolackedthe4.4kbEcoRI“T”fragment,the4.5kbterminal
Hind I I I“ V ”f r a g m e n t ,a n da3 . 5 k bf o r mo fHindIII “V”
that derives from genomes that lack a terminal a sequence
[9, 10] (Figures 2(c) and 2(d)). Clustering of these missing
fragmentssuggestedadeletion distaloftheBACoriinsertion
site (Figure 2(a)). Targeted DNA sequencing conﬁrmed that
all BAC clones have ∼7kb deletions to the right of BAC ori
that impact ORFs US29-TRS1 (Figure 2(a)).
A 3.4kbBglII fragment was unique to all three BAC
clones and BAC-derived viruses (Figure 2(e)). Sequencing of
TL12 revealed that this fragment is due to a mutation from G
to T at position 207132 in the VR-977 sequence [13]w h i c h
creates a novel BglII site within US28. That pYD-C29 has a
T at this position suggests that the mutation occurred during
its construction and was incorporated into the BAC clones
through recombination.
A 4.5kbBglII fragment was unique to TL17 virus lacking
the BAC ori (Figure 2(e)). Based on the TL12 sequence,
excision of the BAC ori is predicted to produce a 5.7kbBglII
fragment that contains three reiterated a sequences. If, in
TL17, this fragment contains only one a sequence copy
(which predominates in strain AD169 [21]), a 4.5kbBglII
fragment is predicted. Thus, with the exception of the US29–
TRS1 deletions, based on restriction digests with 4 enzymes,
all three BACs appear to accurately represent varS and varL
genomes present in the vaccine.
3.2. Complete Sequence of TL12. BAC TL12 was fully
sequenced, annotated, and deposited in GenBank
(GQ121041). When compared to VR-977-derived varS
and varL partial sequences (AY315197 and AY446869), TL12
is missing 7657 bp comprising US29, US30, US31, US32,
US34, US34A,a n dTRS1. In addition, TL12 was found to
have mutations relative to wild-type CMV in RL13 (frame-
shifted), UL1 (frameshifted), UL40 (partially deleted),
UL130 (frame-shifted), US1 (prematurely terminated), US9
(frameshifted), and US28 (truncated). The mutation in US9
probably constitutes a natural variant, as it is shared with
other CMV strains [22]. The US28 and US29 mutations are
unique to TL12 because of the cloning procedure, whereas
each of the others is present in previous sequences obtained
from“Townestrain”(varS)laboratorystocksandtheVR-977
mixture [13, 23–26] .T h eGt oTc h a n g ei nUS28 (position
207132, discussed above) is silent. However, sequences were
also missing from the 3  e n do ft h eUS28 ORF, due to a ﬂaw
in pYD-C29 that resulted from an error in the strain AD169
sequence. This resulted in loss of 30 and addition of 4 novel
amino acid residues at the C terminus of US28. Similarly, the
US29-TRS1 deletion removed the 3  end of US29, modifying
the ORF to remove 78 residues from the C terminus and
replacing them with 152 residues of novel sequence.
These data suggest that, during in vitro passage, varL
evolved from the original wild-type Towne clinical isolate
by acquiring mutations in RL13, UL1, UL40, UL130, and
US1; then, varS arose from varL by deletion/duplication of
UL sequences. Thus, only these ﬁve mutations appear to dif-
ferentiate varL, as found in the vaccine, from the presumed
wild-type CMV sequence.
3.3. Growth Properties of TS15, TL12, and TL17 in Fibroblasts.
Growth curves for BAC-derived viruses were determined
using MRC-5 ﬁbroblast cells. At an MOI of 0.1, BAC-
d e r i v e dv i r u s e se x h i b i t e dm o d e s tg r o w t hd e l a y so nd a y s4
and 6, but by day 8 achieved titers similar to the Towne
mixture (Figure 3(a)). The growth delay was slightly more
pronounced at an MOI of 0.05, but by day 10 the BAC-
derived viruses reached titers only slightly lower than those
of the vaccine-derived mixture or vaccine-derived varS and
varL viruses (Figure 3(b)). These growth impairments are
most likely attributable to the lack of TRS1 in the BAC-
derived viruses, as similar growth impairments at low MOI
have been reported for TRS1-deletion mutants of strain
AD169 [27].
3.4. Entry and Spread of TS15, TL12, and TL17 Is Impaired in
Epithelial Cells. CMV entry into endothelial and epithelial
cells utilizes an endocytic pathway that requires the virion-
associated gH/gL/UL128-UL131 complex comprised of gH,
gL, UL128, UL130, and UL131 (also known as UL131A
[28, 29]). Laboratory varS stocks contain a TT insertion in
UL130 that has been associated with ineﬃcient entry and
replication in endothelial cells [30, 31]. The TL12 sequenceJournal of Biomedicine and Biotechnology 5
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Figure 3: Growth curves of BAC-derived viruses and viruses derived from the vaccine. MRC-5 cultures were infected at MOIs of 0.1 (left)
and 0.05 (right) with the vaccine virus mixture (Towne mix), varS, or varL viruses isolated fromthe vaccine and BAC-derived viruses lacking
(-cre) or containing the BAC ori. Titers of each virus in the culture supernatants were determined on the days indicated.
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Figure 4: Entry and spread of BAC-derived viruses in MRC-5 or ARPE-19 cells. Conﬂuent cell monolayers were infected with matched
inocula (104 pfu) of the indicated GFP+ viruses. Representative micrographs (8X ﬁnal magniﬁcation) were taken on the days indicated.
and targeted sequencing of TS15 and TL17 conﬁrmed that
all three vaccine-derived BACs retain the TT insertion in
UL130. To determine whether the endocytic entry pathway is
similarly impaired in these BAC-derived viruses, eﬃciencies
of viral entry and spread were compared between ﬁbroblasts
and epithelial cells. MRC-5 and ARPE-19 cells were infected
with replicate inocula of GFP+ viruses and monitored for
green ﬂuorescence on day 3 to assess entry and at later
times to assess spread. Compared to entry into MRC-5s,
TS15, TL12, and TL17 entered ARPE-19 epithelial cells
with very poor eﬃciency; however, after entry TS15 and
TL17 spread slowly in ARPE-19 cells, whereas TL12 did not
(Figure 4).Incontrast,controlvirusBADrUL131-Y4,aGFP-
tagged virus known to replicate eﬃciently in epithelial cells
[14], entered both cell types eﬃciently. Viral titers in the
supernatants of TS15- or TL17-infected ARPE-19 cells did6 Journal of Biomedicine and Biotechnology
not exceed 4×102 pfu/mL, compared to 3×105 pfu/mL in
MRC-5 cells, indicating a severe restriction to replication in
epithelial cells that is consistent with the above observations
of ineﬃcient entry and spread.
4. Discussion
The Towne vaccine has been well characterized in vivo
through clinical trials that involved nearly 1000 human
subjects. Remarkably, the viruses that comprise the vaccine
have not been studied directly. Instead, in vitro data
pertaining to the Towne strain has been obtained from
laboratory stocks having uncertain lineage with respect to
the vaccine. Presumptions that these data apply to the
vaccine involve considerable risk. For example, because
the ﬁrst characterized laboratory stocks of strain Towne
were exclusively varS, the possibility that the vaccine might
c o n t a i nl e s sd e l e t e df o r m so ft h eC M Vg e n o m e( i . e . ,v a r L )
was for many years overlooked. As we now consider genetic
modiﬁcations intended to improve vaccine immunogenicity
and eﬃcacy while maintaining safety, it is imperative to have
an accurate description of the genotypic and phenotypic
properties of the viruses that were evaluated in vivo.
Moreover, next-generation Towne-based vaccines should be
based not on laboratory stocks but on vaccine-derived viral
genomes.
BAC cloning allowed the isolation, with minimal passage
in vitro, of viral genomes representing the vaccine. The fact
that among the BAC clones varS and varL genomes were
present in roughly equal proportions suggests that, like VR-
977, the vaccine is a mixture of the two variant genome
types. This result is concordant with unpublished restriction
and targeted sequence analyses suggesting the presence of
varL genomes in vaccine lot C-107 (Greg Duke, personal
communication). This ﬁnding conﬁrms that the vaccine’s
safety history applies to varL as well as to varS genomes
(a conclusion that could not be made if vaccine lots tested
in humans had been found to contain only varS viruses).
Therefore, varL should provide an acceptable starting point
for future vaccine development. To this end, restriction
analyses, sequencing, and growth properties in ﬁbroblasts
suggest that, with exception of mutations in US28 and US29
and deletion of US130-TRS1, the BAC clones are accurate
representations of viruses comprising the vaccine. Moreover,
as the BAC ori/GFP cassette is ﬂanked by LoxP sites, the
inserted foreign sequences can be easily excised with Cre
recombinase, leaving only 35bp (one LoxP site) of nonviral
sequences.
The US130-TRS1 deletions that we observed were most
likely compensatory in response to the increase in genome
length caused by insertion of the 9.1-kb BAC ori/GFP
cassette. Very similar deletions (also adjacent to BAC ori
insertions) were previously observed in initial BAC clones
of the guinea pig cytomegalovirus genome [20]. Further
studies demonstrated that guinea pig cytomegalovirus does
not tolerate genomes over length by 9kb, presumably due
to restrictions imposed by the packaging capacity of the
capsid [32]. This problem may be particularly acute for
cytomegaloviruses, as their genomes are the largest of the
Herpesviridae. Currently the only solution is to repair the
deletions using E. coli genetics, although in theory it may
be possible to clone full-length herpesvirus genomes in-
dependent of packaging-imposed size restrictions by in
vitro transposition of BAC ori into viral DNA, followed by
transformation directly into E. coli, as has been suggested
[33].
Sequence data from the BAC clones conﬁrmed the
presence of ﬁve potential attenuating mutations (RL13, UL1,
UL40, UL130, and US1) in varL viruses comprising the
vaccine. This information may provide the basis for future
modiﬁcations designed to modify attenuation or enhance
immunogenicity. For example, the UL130 mutation was
shown to impair endothelial and epithelial but not ﬁbroblast
tropism of laboratory stocks by modifying the C-terminus
of UL130 and impairing assembly and virion incorporation
of gH/gL/UL128-UL131 complexes [30, 31]. That vaccine
viruses contain the same mutation and exhibit similar
restricted tropism in vitro suggests that in vivo the UL130
mutation contributes to safety of the vaccine by limiting
the cells available for viral replication and dissemination
to those of ﬁbroblast/mesenchymal lineage. Conversely,
suboptimal eﬃcacy of the Towne vaccine may be linked to its
failure to induce robust epithelial entry-speciﬁc neutralizing
antibody responses [15]. As potent epithelial entry-speciﬁc
neutralizing epitopes reside within gH/gL/UL128-UL131
complexes [34, 35], repair of the UL130 mutation (and
consequent restoration of gH/gL/UL128-UL131 complex
formation) may be essential for improving vaccine eﬃ-
cacy.
Thus, it may be necessary to accompany modiﬁcations
designed to improve immunogenicity and eﬃcacy with
strategies to maintain or improve safety. For example, repair
of UL130 could be accompanied by additional mutations
that allow assembly of nonfunctional but antigenically native
gH/gL/UL128-UL131complexes,thusmaintainingrestricted
tropism while expressing important neutralizing epitopes. In
addition, mutations that partially impair viral replication in
vitro(suchastheUS130-TRS1deletionsdescribedhere)may
servetoenhancesafetybylimitingreplicationinvivo.Finally,
viruses incapable of replication in vivo could be constructed
by creation of conditional lethal mutations (which would
require special in vitro culture conditions for propagation),
or more simply by inactivation of infectious virus in vitro
prior to immunization.
Towards the development of such rationally engineered
whole-virus-based CMV vaccines, the BAC clones described
here provide deﬁned reagents of known provenance that can
be readily manipulated with existing genetic technologies.
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